Ozempic Shows Promise in Reducing Kidney Disease Risks and Mortality
TL;DR Summary
A major clinical trial has found that semaglutide, the active ingredient in Ozempic, significantly reduces the risk of kidney complications, heart issues, and death in people with Type 2 diabetes and chronic kidney disease. The promising results led Novo Nordisk to halt the trial early and seek FDA approval to update Ozempic's label to include these benefits.
- Ozempic May Help Treat Kidney Disease, Study Finds The New York Times
- Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial Yahoo! Voices
- Novo's Ozempic Slashes Risk of Death in Kidney Disease Study Bloomberg
- Ozempic cut risk of death in diabetes patients with chronic kidney disease STAT
- FLOW Study, Dialysis Developments, CKD Treatment Key at ERC Medscape
Reading Insights
Total Reads
0
Unique Readers
20
Time Saved
2 min
vs 3 min read
Condensed
88%
482 → 57 words
Want the full story? Read the original article
Read on The New York Times